Novartis diabetes drug faces three month delay
14th Nov 2006, 06:12 GMT
Novartis has delayed its anti-diabetes medicine Galvus by three months after submitting additional clinical data to the FDA, sending its shares down.
Novartis diabetes drug faces three month delay related news:
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
- U.S. delays Novartis diabetes drug — Marketplace by Bloomberg - International Herald Tribune
- Novartis diabetes drug delayed — FT.com - Companies
- Novartis Diebetes Drug Gets FDA Setback — StratWire - Business of Healthcare NewsFeed
- Delay for FDA approval of diabetes drug — WISTV - Health
- FDA Review on Novartis Galvus Extended — Government/ Industry Regulation News from StratCenter.com
- Novartis announces three-month extension of US regulatory review for Galvus® to assess recently available clinical data — WebWire - Recent Headlines
- Diabetes drug may cut heart risks — MSNBC.com: Health
- Diabetes drug may reduce cardiovascular risks — EurekAlert! - Medicine and Health
Latest news from Pharmaceutical Business Review Latest News:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol
- ZymoGenetics, Serono present positive results for atacicept